Jianming Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianming Hu has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Chun-Xia Liu
Department of Cardiology, Cardiovascular Institute of Chengdu, The Third People’s Hospital of Chengdu, Chengdu, China
2 shared publications - Feng Li
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 shared publications Lianghai Wang
Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases (Ministry of Education)/Department of Pathology, the First Affiliated Hospital, Shihezi University School of Medicine, Xinjiang, China
2 shared publications- Shugang Li
School of General Practice and Continuing Education Capital Medical University Beijing China
2 shared publications Weihua Liang
Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases (Ministry of Education)/Department of Pathology, the First Affiliated Hospital, Shihezi University School of Medicine, Xinjiang, China
2 shared publicationsWeinan Wang
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-19
A Multifunctional Metal-Based Nanomedicine for Copper Sequestration, in situ Toxification, and Immune Activation Against Metastatic Cancer
Objective: Tumor metastasis remains the principal cause of cancer-related mortality. However, current therapies often fail to effectively control both primary and disseminated lesions. Copper ions (Cu2⁺) are increasingly being recognized as key regulators of tumor progression, metastasis, and immune evasion. Leveraging their tumor-promoting properties as therapeutic targets is a promising anticancer strategy. Methods: In this study, a multifunctional nanoplatform based on hyaluronic acid (HA)-stabilized and manganese-diethyldithiocarbamate (MnET) complex-loaded manganese dioxide (MnO2) nanosheets, denoted as MMH (MnET@MnO2–HA), was designed to deplete Cu2⁺ in the tumor microenvironment and simultaneously generate bioactive copper-diethyldithiocarbamate (CuET) in situ. MMH was systematically evaluated in terms of drug release, Cu2+ sequestration, in situ toxicity, and immune activation against primary and metastatic tumors, through both in vitro and in vivo experiments using animal models. Results: MMH exhibited CD44-targeted uptake, GSH- and pH-responsive drug release, and tumor-selective bioactivity. MMH efficiently scavenged Cu2⁺ within tumor cells, leading to the formation of CuET, which induced immunogenic cell death (ICD), marked by the release of damage associated molecular patterns (DAMPs). This process facilitated M1 macrophage repolarization, CD8⁺ T cell infiltration, and the activation of type I interferon signaling via Mn2⁺-mediated interferon regulatory factor 3 (IRF3) phosphorylation. Furthermore, MMH suppressed epithelial-mesenchymal transition (EMT) and vascular endothelial growth factor A (VEGF-A) expression, thereby impairing angiogenesis and metastatic spread. In murine 4T1 breast cancer models, MMH potently inhibited both primary and distant metastatic tumors without systemic toxicity. Conclusion: MMH would be a promising approach for treating aggressive and metastatic cancers through metal-based immunometabolic intervention.
- 1 October 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-19
Open AccessA Multifunctional Metal-Based Nanomedicine for Copper Sequestration, in situ Toxification, and Immune Activation Against Metastatic Cancer
Objective: Tumor metastasis remains the principal cause of cancer-related mortality. However, current therapies often fail to effectively control both primary and disseminated lesions. Copper ions (Cu2⁺) are increasingly being recognized as key regulators of tumor progression, metastasis, and immune evasion. Leveraging their tumor-promoting properties as therapeutic targets is a promising anticancer strategy. Methods: In this study, a multifunctional nanoplatform based on hyaluronic acid (HA)-stabilized and manganese-diethyldithiocarbamate (MnET) complex-loaded manganese dioxide (MnO2) nanosheets, denoted as MMH (MnET@MnO2–HA), was designed to deplete Cu2⁺ in the tumor microenvironment and simultaneously generate bioactive copper-diethyldithiocarbamate (CuET) in situ. MMH was systematically evaluated in terms of drug release, Cu2+ sequestration, in situ toxicity, and immune activation against primary and metastatic tumors, through both in vitro and in vivo experiments using animal models. Results: MMH exhibited CD44-targeted uptake, GSH- and pH-responsive drug release, and tumor-selective bioactivity. MMH efficiently scavenged Cu2⁺ within tumor cells, leading to the formation of CuET, which induced immunogenic cell death (ICD), marked by the release of damage associated molecular patterns (DAMPs). This process facilitated M1 macrophage repolarization, CD8⁺ T cell infiltration, and the activation of type I interferon signaling via Mn2⁺-mediated interferon regulatory factor 3 (IRF3) phosphorylation. Furthermore, MMH suppressed epithelial-mesenchymal transition (EMT) and vascular endothelial growth factor A (VEGF-A) expression, thereby impairing angiogenesis and metastatic spread. In murine 4T1 breast cancer models, MMH potently inhibited both primary and distant metastatic tumors without systemic toxicity. Conclusion: MMH would be a promising approach for treating aggressive and metastatic cancers through metal-based immunometabolic intervention.
- Open Access
- 13 April 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Focal adhesion kinase promotes biphasic differentiation and induces infiltration and metastasis of synovial sarcoma
Synovial sarcoma is a malignant tumor of mesenchymal origin, which is characterized by the simultaneous expression of epithelia and mesenchyme. Tumor micro
- 13 April 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessFocal adhesion kinase promotes biphasic differentiation and induces infiltration and metastasis of synovial sarcoma
Synovial sarcoma is a malignant tumor of mesenchymal origin, which is characterized by the simultaneous expression of epithelia and mesenchyme. Tumor micro
- Open Access
- 14 January 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-19
M2 tumor-associated macrophage mediates the maintenance of stemness to promote cisplatin resistance by secreting TGF-β1 in esophageal squamous cell carcinoma
Background: Esophageal squamous cell carcinoma (ESCC) is a deadly gastrointestinal malignancy, and chemotherapy resistance is a key factor leading to its poor prognosis. M2 tumor-associated macrophages (M2-TAMs) may be an important cause of chemoresistance in ESCC, but its exact mechanism is still unclear. Methods: In order to study the role of M2-TAMs in ESCC chemoresistance, CCK-8, clone formation assay, flow cytometric apoptosis assay, qRT-PCR, western blotting, and serum-free sphere formation assays were used. In vivo animal experiments and human ESCC tissues were used to confirm the findings. Results: In vitro and in vivo animal experiments, M2-TAMs reduced the sensitivity of ESCC cells to cisplatin. Mechanistically, M2-TAMs highly secreted TGF-β1 which activated the TGFβR1-smad2/3 pathway to promote and maintain the stemness characteristic of ESCC cells, which could inhibit the sensitivity to cisplatin. Using TGFβ signaling inhibitor SB431542 or knockdown of TGFβR1 could reverse the cisplatin resistance of ESCC cells. In 92 cases of human ESCC tissues, individuals with a high density of M2-TAMs had considerably higher levels of TGF-β1. These patients also had worse prognoses and richer stemness markers. Conclusion: TGF-β1 secreted from M2-TAMs promoted and maintained the stemness characteristic to induce cisplatin resistance in ESCC by activating the TGFβ1-Smad2/3 pathway.
- 14 January 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-19
Open AccessM2 tumor-associated macrophage mediates the maintenance of stemness to promote cisplatin resistance by secreting TGF-β1 in esophageal squamous cell carcinoma
Background: Esophageal squamous cell carcinoma (ESCC) is a deadly gastrointestinal malignancy, and chemotherapy resistance is a key factor leading to its poor prognosis. M2 tumor-associated macrophages (M2-TAMs) may be an important cause of chemoresistance in ESCC, but its exact mechanism is still unclear. Methods: In order to study the role of M2-TAMs in ESCC chemoresistance, CCK-8, clone formation assay, flow cytometric apoptosis assay, qRT-PCR, western blotting, and serum-free sphere formation assays were used. In vivo animal experiments and human ESCC tissues were used to confirm the findings. Results: In vitro and in vivo animal experiments, M2-TAMs reduced the sensitivity of ESCC cells to cisplatin. Mechanistically, M2-TAMs highly secreted TGF-β1 which activated the TGFβR1-smad2/3 pathway to promote and maintain the stemness characteristic of ESCC cells, which could inhibit the sensitivity to cisplatin. Using TGFβ signaling inhibitor SB431542 or knockdown of TGFβR1 could reverse the cisplatin resistance of ESCC cells. In 92 cases of human ESCC tissues, individuals with a high density of M2-TAMs had considerably higher levels of TGF-β1. These patients also had worse prognoses and richer stemness markers. Conclusion: TGF-β1 secreted from M2-TAMs promoted and maintained the stemness characteristic to induce cisplatin resistance in ESCC by activating the TGFβ1-Smad2/3 pathway.
- Open Access
- 27 November 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (1) , e24082
Long non‐coding RNA MIR31HG as a prognostic predictor for malignant cancers: A meta‐ and bioinformatics analysis
Background: The possible regulatory mechanism of MIR31HG in human cancers remains unclear, and reported results of the prognostic significance of MIR31HG expression are inconsistent.Methods: The meta‐analysis and related bioinformatics analysis were conducted to evaluate the role of MIR31HG in tumor progression.Results: The result showed that high MIR31HG expression was not related to prognosis. However, in the stratified analysis, we found that the overexpression of MIR31HG resulted in worse OS, advanced TNM stage, and tumor differentiation in respiratory system cancers. Moreover, our results also found that MIR31HG overexpression was related to shorter OS in cervical cancer patients and head and neck tumors. In contrast, the MIR31HG was lower in digestive system tumors which contributed to shorter overall survival, advanced TNM stage, and distant metastasis. Furthermore, the bioinformatics analysis showed that MIR31HG was highly expressed in normal urinary bladder, small intestine, esophagus, stomach, and duodenum and low in colon, lung, and ovary. The results obtained from FireBrowse indicated that MIR31HG was highly expressed in LUSC, CESC, HNSC, and LUAD and low in STAD and BLCA. Gene Ontology analysis showed that the co‐expressed genes of MIR31HG were most enriched in the biological processes of peptide metabolism and KEGG pathways were most enriched in Ras, Rap1, and PI3K‐Akt signaling pathway.Conclusion: MIR31HG may serve as a potential biomarker in human cancers.
- 27 November 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (1) , e24082
Open AccessLong non‐coding RNA MIR31HG as a prognostic predictor for malignant cancers: A meta‐ and bioinformatics analysis
Background: The possible regulatory mechanism of MIR31HG in human cancers remains unclear, and reported results of the prognostic significance of MIR31HG expression are inconsistent.Methods: The meta‐analysis and related bioinformatics analysis were conducted to evaluate the role of MIR31HG in tumor progression.Results: The result showed that high MIR31HG expression was not related to prognosis. However, in the stratified analysis, we found that the overexpression of MIR31HG resulted in worse OS, advanced TNM stage, and tumor differentiation in respiratory system cancers. Moreover, our results also found that MIR31HG overexpression was related to shorter OS in cervical cancer patients and head and neck tumors. In contrast, the MIR31HG was lower in digestive system tumors which contributed to shorter overall survival, advanced TNM stage, and distant metastasis. Furthermore, the bioinformatics analysis showed that MIR31HG was highly expressed in normal urinary bladder, small intestine, esophagus, stomach, and duodenum and low in colon, lung, and ovary. The results obtained from FireBrowse indicated that MIR31HG was highly expressed in LUSC, CESC, HNSC, and LUAD and low in STAD and BLCA. Gene Ontology analysis showed that the co‐expressed genes of MIR31HG were most enriched in the biological processes of peptide metabolism and KEGG pathways were most enriched in Ras, Rap1, and PI3K‐Akt signaling pathway.Conclusion: MIR31HG may serve as a potential biomarker in human cancers.
- Open Access
- 27 September 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (54) , 92454-92469
MicroRNA-34a functions as a tumor suppressor by directly targeting oncogenic PLCE1 in Kazakh esophageal squamous cell carcinoma
MicroRNA-34a functions as a tumor suppressor by directly targeting oncogenic PLCE1 in Kazakh esophageal squamous cell carcinoma MicroRNA-34a functions as a tumor suppressor by directly targeting oncogenic PLCE1 in Kazakh esophageal squamous cell carcinoma
- 27 September 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (54) , 92454-92469
Open AccessMicroRNA-34a functions as a tumor suppressor by directly targeting oncogenic PLCE1 in Kazakh esophageal squamous cell carcinoma
MicroRNA-34a functions as a tumor suppressor by directly targeting oncogenic PLCE1 in Kazakh esophageal squamous cell carcinoma MicroRNA-34a functions as a tumor suppressor by directly targeting oncogenic PLCE1 in Kazakh esophageal squamous cell carcinoma
- 1 May 2015
- Published by Elsevier in Human Pathology
- Vol. 46 (5) , 707-715
ORAOV1 overexpression in esophageal squamous cell carcinoma and esophageal dysplasia: a possible biomarker of progression and poor prognosis in esophageal carcinoma
- 1 May 2015
- Published by Elsevier in Human Pathology
- Vol. 46 (5) , 707-715
ORAOV1 overexpression in esophageal squamous cell carcinoma and esophageal dysplasia: a possible biomarker of progression and poor prognosis in esophageal carcinoma
- Open Access
- 17 May 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5) , e62971
Analysis of PTEN Methylation Patterns in Soft Tissue Sarcomas by MassARRAY Spectrometry
Soft tissue sarcomas (STSs) are a rare and fascinating group of diseases that can be subdivided into specific reciprocal translocations in STSs (SRTSs) and nonspecific reciprocal translocations in STSs (NRTSs). PTEN mutations are rare in STSs, suggesting that PTEN expression may be lost by alternative mechanisms such as methylation. In order to reveal whether aberrant PTEN methylation occurs in STSs, MassARRAY Spectrometry was carried to detect methylation patterns of PTEN in STSs. We evaluated methylation levels in 41 CpG sites from −2,515 to −2,186 bp (amplicon A) and −1,786 to −1,416 bp (amplicon B) relative to the translation initiation site in 110 different cases (46 cases of SRTSs, 40 cases of NRTSs, and 24 cases of normal controls). In addition, immunohistochemistry (IHC) was used to detect the loss of PTEN to determine whether PTEN alterations were responsible for decreased PTEN expression. Our data showed that expression of PTEN was diminished in 49 (57%) STSs, whereas the remaining cases (43%) were classified as high expression. Our previous results found that only 2 of 86 cases (2.3%) had a PTEN mutation suggesting that PTEN may be mainly downregulated in STSs by methylation, but not by mutation of PTEN itself. We observed that amplicon A was hypermethylated in STSs with low PTEN expression, whereas normal controls had low methylation levels (P0.05), nor were there significant differences in the methylation levels in PTEN between SRTS and NRTS cases. The majority of individual CpG units within two amplicons was demonstrated to be hypermethylated. These findings indicate that PTEN hypermethylation is a common event in STSs suggesting that the inactivation of PTEN may be due to hypermethylation in the promoter of PTEN. The aberrant methylation of the CpG sites within PTEN promoter may serve as a potential candidate biomarker for STSs.
- 17 May 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5) , e62971
Open AccessAnalysis of PTEN Methylation Patterns in Soft Tissue Sarcomas by MassARRAY Spectrometry
Soft tissue sarcomas (STSs) are a rare and fascinating group of diseases that can be subdivided into specific reciprocal translocations in STSs (SRTSs) and nonspecific reciprocal translocations in STSs (NRTSs). PTEN mutations are rare in STSs, suggesting that PTEN expression may be lost by alternative mechanisms such as methylation. In order to reveal whether aberrant PTEN methylation occurs in STSs, MassARRAY Spectrometry was carried to detect methylation patterns of PTEN in STSs. We evaluated methylation levels in 41 CpG sites from −2,515 to −2,186 bp (amplicon A) and −1,786 to −1,416 bp (amplicon B) relative to the translation initiation site in 110 different cases (46 cases of SRTSs, 40 cases of NRTSs, and 24 cases of normal controls). In addition, immunohistochemistry (IHC) was used to detect the loss of PTEN to determine whether PTEN alterations were responsible for decreased PTEN expression. Our data showed that expression of PTEN was diminished in 49 (57%) STSs, whereas the remaining cases (43%) were classified as high expression. Our previous results found that only 2 of 86 cases (2.3%) had a PTEN mutation suggesting that PTEN may be mainly downregulated in STSs by methylation, but not by mutation of PTEN itself. We observed that amplicon A was hypermethylated in STSs with low PTEN expression, whereas normal controls had low methylation levels (P0.05), nor were there significant differences in the methylation levels in PTEN between SRTS and NRTS cases. The majority of individual CpG units within two amplicons was demonstrated to be hypermethylated. These findings indicate that PTEN hypermethylation is a common event in STSs suggesting that the inactivation of PTEN may be due to hypermethylation in the promoter of PTEN. The aberrant methylation of the CpG sites within PTEN promoter may serve as a potential candidate biomarker for STSs.